Sonidegib and vismodegib are Hedgehog pathway inhibitors (HhIs) that play a relevant role in the management of locally advanced basal cell carcinoma (laBCC). This study compared the efficacy and safety of both HhIs based on their available data using effect size measures such as number needed to treat (NNT), number needed to harm (NNH), and likelihood to be helped or harmed (LHH).

Benefit-risk assessment of sonidegib and vismodegib in the treatment of locally advanced basal cell carcinoma

Zalaudek, Iris;
2022

Abstract

Sonidegib and vismodegib are Hedgehog pathway inhibitors (HhIs) that play a relevant role in the management of locally advanced basal cell carcinoma (laBCC). This study compared the efficacy and safety of both HhIs based on their available data using effect size measures such as number needed to treat (NNT), number needed to harm (NNH), and likelihood to be helped or harmed (LHH).
Pubblicato
https://www.drugsincontext.com/benefit-risk-assessment-of-sonidegib-and-vismodegib-in-the-treatment-of-locally-advanced-basal-cell-carcinoma/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281973/
File in questo prodotto:
File Dimensione Formato  
dic.2022-1-2.pdf

accesso aperto

Tipologia: Documento in Versione Editoriale
Licenza: Creative commons
Dimensione 403.82 kB
Formato Adobe PDF
403.82 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11368/3027605
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact